US-based Cardurion Pharmaceuticals has completed enrolment in two multi-centre, global Phase II CYCLE trials of the orally-administered phosphodiesterase 9 (PDE9) inhibitor, CRD-750, targeting both ...

A new study published in the European Journal of Medical Research revealed that dapagliflozin, a sodium-glucose ...

Early symptoms like fatigue, breathlessness, swelling mimic common heart issues, causing cardiac amyloidosis to go undetected ...

An anti-hazing network honors a UVA leader, the American Heart Association lauds UVA Health for heart and stroke care, and ...

Q2 2025 Earnings Call Transcript August 5, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $6.02, expectations ...

Amgen AMGN reported second-quarter 2025 adjusted earnings of $6.02 per share, which beat the Zacks Consensus Estimate of ...